GLP-1 Daily: Ozempic & Wegovy News
CDC: Two in Five GLP-1 Users Change How They Take It, Often Over Cost
Friday, November 13, 2026 · 6 min
A CDC survey published Thursday finds about one in ten U.S. adults used a GLP-1 in the past year, one in five of them a compounded version, and 44 percent changed their doses from what was prescribed, often over cost or availability. Also: China approves Lilly's orforglipron pill, and health systems describe the strain of Medicare's GLP-1 Bridge.
Listen
Show notes
A CDC survey published Thursday finds about one in ten U.S. adults used a GLP-1 in the past year, one in five of them a compounded version, and 44 percent changed their doses from what was prescribed, often over cost or availability. Also: China approves Lilly's orforglipron pill, and health systems describe the strain of Medicare's GLP-1 Bridge.
In this episode
- Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025 | MMWR — CDCMMWR
“Based on data from CDC’s Rapid Surveys System collected during July–August 2025, approximately one in 10 adults reported GLP-1 medication use in the past year. Among GLP-1 medication users, approximately one in five reported taking a compounded version. Approximately two in five…”
- GLP-1 weight-loss pills expand to China as US firm wins approval | The Independent — The Independent
“Chinese regulators have approved Eli Lilly's orforglipron, making the US company the first drugmaker to win clearance in the country for a GLP-1 weight-loss pill. The decision, announced on Thursday, hands Lilly an early advantage over its Danish rival Novo Nordisk in the…”
- Ascension Wisconsin vs. Cleveland Clinic: 2 approaches to the GLP-1 Bridge demand - Becker's Hospital Review — Beckershospitalreview
“Dr. Weber said some patients arrived July 1 expecting the drug for $50 a month, only to learn they did not qualify. That required “some service recovery,” he said.”